SanaClis’ Post

As we step into the last day of BIO International Convention 2024, we are filled with a mix of excitement and gratitude. This week has been a whirlwind of innovation, collaboration, and inspiration. A big thank you to everyone who has contributed to making this conference a success. Here's to a productive and inspiring final day! Contact us today to discuss how Intrinseque Health can create a robust clinical supply plan for your clinical development programs. contact@intrinsequehealth.com https://lnkd.in/gPWaDs_n #drugdiscovery #drugdevelopment #studystartup #clinicaltrials #healthcare #clinicalresearch #patientrecruitment #sitemanagement #clinicaldevelopment #clinicaltrial #clinicaloperations #clinicalstudy #clinicalsupply

So enlightening to learn how the need for LM is felt in different important departments of administration.

Had a wonderful time (as always) at the Oregon Bioscience Incubator and OTRADI monthly meetup last night. It was an especially informative session thanks to the panel discussion on Bioethics and Healthcare Decisions. A very engaged and thoughtful discussion with doctors Ruchi Thanawala, Murtaza Batla and William Hersh, MD. A key observation for me was the challenge practitioners face today as patients (admirably) do research to be better informed. In today's information age, practitioners encounter three main types of information when interacting with patients: * Information - True facts * Misinformation - Well-intentioned, but incorrect information * Disinformation - False facts spread on purpose I imagine it is especially challenging here in the U.S. where we are one of just two countries which allow direct-to-consumer drug ads on t.v. and other media. Do the people who see those ads critically evaluate them, comparing the improvements over a placebo? Add to that the misinformation and disinformation on the web and I can see it straining the ability of the provider to do the best for their patient. While the interplay of information trio is not unique to healthcare, its direct impact on patient health significantly heightens the challenge.

This new service looks like a well intended repository to me with some good graphics and flow diagrams to simplify existing regulations and guidance. However…… There is still a long way to go in harmonising NHS standards and compliance between International Standards (ISO 14971 & ISO 27001) to make the transition easier for medical device manufacturers. Where possible, when we support clients at 8foldGovernance we try to harmonise documentation to prevent duplication and territorial silos of policies and procedures. In addition, I am not sure if the service sign posts developers to the risks of crossing into a stand alone regulatory activity - which the CQC discuss in their own regulated activity guidance.  I have discussed this is a blog previously published - https://lnkd.in/dbKvEzXa Hopefully this is just the start of a very useful resource! #jointhe8fold

This Commentary by Health and Environmental Sciences Institute (HESI) Director, Dr. Syril Pettit, DrPH, asserts that the challenges of realizing the systems-level changes needed to catalyze the broad-scale adoption and use of New Approach Methodologies #NAMs may be less unique than perceived to date, and points to specific opportunities to learn from decades of experience from the Quality Improvement #QI movement in the #publichealth and #healthcare arenas. Read the full article at the link below. https://lnkd.in/gBg6BW8g

The Duke-NUS Centre of Regulatory Excellence (CoRE) is set to commemorate its 10th anniversary on the 14 th – 15 th October 2024, with a landmark event—the CoRE Scientific Conference themed & "Regulating the Future of Health: Converging Products & Services Regulation for Access, Innovation & Sustainability." This event, along with a Celebratory Networking Evening and Graduation Ceremony, marks a significant milestone in CoRE's decade-long journey of achievements and contributions to the field of health regulation. This year's event is a unique platform for professionals, policymakers, and thought leaders across MedTech, Pharma, and Healthcare to collaboratively tackle pressing regulatory challenges. The programme is designed around four exciting themes—Regulating Artificial Intelligence & Digital Health, Regulating Precision Medicine, Regulating for Disease Prevention, and Partnerships for Effective Regulation—with an aim to foster meaningful dialogues, shape future perspectives, and enhance collaboration among key stakeholders in the regulatory ecosystem.

How to prevent your MedTech product from being left behind . . .   Steering clear of a fate where your product remains dormant, whether physically or symbolically, is paramount. But how do you ensure this?   Jackie Leach Scully, the esteemed Professor of Bioethics at the University of New South Wales, talks to us about the intriguing realm of PPIE (Patient and Public Involvement and Engagement).   Is PPIE just a mandatory checkbox for grant-funded projects, or is it an indispensable cornerstone of robust product development and successful market entry?   Welcoming patient and public involvement and engagement isn't a mere roadblock on your product's launch journey; it's an essential stride that every visionary innovator should enthusiastically take.   Listen here >> https://lnkd.in/expiNaKh   #MedTechForBeginners #PymsConsultancy #PymsPodcast #NHS #Medtech #MedicalDevices #BioethicsTalks #PPIEInsights #InnovationEthics

💊🚀Do you often forget to take your meds? Did you know this phenomenon has a name, multiple consequences, and a project designed to address them? A new RIVA Illustrations production to spread awareness about ADHERENCE thanks to the collaboration with Gaye Hafez 💊🚀 #digitalhealth #pharmacy #primarycare #pharmacology #MATech COST Association - European Cooperation in Science and Technology

🫵 Folks, if you are interested in Healthcare and Transactions, this is a know how piece you should not pass☝️: Read the Spring 2024 edition of our #Healthcare & #LifeSciences Market Update, in this edition we explore regulatory developments affecting life sciences and digital health, as well as the deal drivers and licensing trends of 2024. https://lw.link/XKUmPh

Read the Spring 2024 edition of our #Healthcare & #LifeSciences Market Update, in this edition we explore regulatory developments affecting life sciences and digital health, as well as the deal drivers and licensing trends of 2024. https://lw.link/860Jkd